Genflow Biosciences has entered into two Confidential Disclosure Agreements (CDAs) with leading animal health companies, the company said. These agreements are intended to facilitate data exchange and initiate discussions on potential collaborations.
The CDAs align with Genflow’s strategy to apply its proprietary SIRT6-centenarian gene therapy platform in both human and animal health. The company said its ongoing GF-1004 dog aging study (in beagles) has thus far reported no adverse events.
Under the new agreements, Genflow seeks to evaluate partnership opportunities aimed at extending healthspan and improving quality of life in companion animals, a segment identified by the company as rapidly growing and high-value.
Genflow claims such collaborations would allow faster paths to commercialization through leveraging partner resources, regulatory expertise and commercial infrastructure. The company said this would help derisk its execution and enhance shareholder value.
Genflow’s lead human-health therapy, GF-1002, delivers a centenarian variant of the SIRT6 gene and is currently being tested in a 12-month proof-of-concept clinical trial in aged dogs, which began in March 2025. The company also plans to begin a clinical trial in 2025 to explore GF-1002 for treating metabolic dysfunction-associated steatohepatitis, a common chronic liver disease with no current effective treatments.
